Aimovig is a brand-name medication that is prescribed to prevent migraine episodes in adults. It is administered via injection, not for treating symptoms as they occur. Common side effects of Aimovig ...

Emgality (galcanezumab-gnlm) is a prescription drug that’s used to help treat and prevent certain types of headaches. Emgality comes as a liquid solution for injection under the skin. If you have ...

Internist Vincent Martin, MD, said every primary care clinician should know about calcitonin gene-related peptide (CGRP) monoclonal antibodies for preventing migraines. These newer drugs are changing ...

Eli Lilly (NYSE:LLY) and Organon (NYSE:OGN) have expanded their commercialization deal for migraine medicine Emgality (galcanezumab) in 11 additional markets. Organon will serve as the sole ...

Automobile engines have undergone tons of changes over the years, primarily to make them more efficient. For the most part though, engine changes result from a string of iterative improvements on ...

Anyone who has gone to school to learn how to repair engines of all types, such as myself, will have learned the fundamentals of how they work. It's crucial for troubleshooting and diagnosing engine ...

Since its advent more than 40 years ago, lethal injection has become by far the most common method of enacting capital punishment in the United States, accounting for the vast majority of executions ...

Two months after a federal judge overturned a $176 million jury verdict against Eli Lilly and Co in a patent infringement lawsuit, the dispute seems to be winding down. Indianapolis-based Lilly and ...

If you’ve ever wondered the secret to Jennifer Aniston’s perpetually perfect hair and complexion, you’re in luck: The 54-year-old just revealed that peptide injections, also known as peptide therapy, ...

If Eli Lilly and Co. had been hoping its migraine drug, Emgality (galcanezumab), would emerge with unequivocal superiority against Pfizer Inc.’s Nurtec ODT (rimegepant orally disintegrating tablet), ...

Eli Lilly And Co (NYSE:LLY) announced the results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet). Emgality did not meet ...